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Gut microbes can profoundly modulate mucosal
barrier-promoting Th17 cells in mammals. A salient
feature of HIV/simian immunodeficiency virus (SIV)
immunopathogenesis is the loss of Th17 cells, which
has been linked to increased activity of the immuno-
modulatory enzyme, indoleamine 2,3-dioxygenase 1
(IDO 1). The role of gut microbes in this system re-
mains unknown, and the SIV-infected rhesus ma-
caque provides a well-described model for HIV-asso-
ciated Th17 loss andmucosal immune disruption. We
observed a specific depletion of gut-resident Lacto-
bacillus during acute and chronic SIV infection of
rhesus macaques, which was also seen in early HIV-
infected humans. This depletion in rhesus macaques
correlated with increased IDO1 activity and Th17
loss. Macaques supplemented with a Lactobacillus-
containing probiotic exhibited decreased IDO1 activ-
ity during chronic SIV infection. We propose that
Lactobacillus species inhibit mammalian IDO1 and
thus may help to preserve Th17 cells during patho-
genic SIV infection, providing support for Lactoba-
cillus species as modulators of mucosal immune
homeostasis.
INTRODUCTION
Untreated HIV infection is characterized by chronic immune
activation, which is postulated to be spurred by decreasedCell Repmucosal barrier function and subsequent translocation of mi-
crobial products into systemic circulation (Klatt et al., 2013b).
The gut mucosa of HIV-infected individuals exhibits a relative
depletion of Th17 cells, a cell type that participates in contain-
ment of gut luminal bacteria and that supports barrier integrity
via secretion of IL-17 and IL-22, cytokines which act on epi-
thelial cells to promote production of antimicrobial peptides
and mucins (Ouyang et al., 2008). Concomitant with Th17 cell
depletion in HIV (which also occurs in non-human primate
models using the closely related simian immunodeficiency
virus [SIV]), has been observed a simultaneous upregulation
of the immunomodulatory enzyme, indoleamine 2,3-dioxyge-
nase 1(IDO1) (Favre et al., 2010). IDO1 is gene-induced primar-
ily in macrophages and plasmacytoid dendritic cells by type I
and II interferons, cytokines that are highly abundant in circula-
tion during untreated HIV/SIV infection (Hosmalin and Lebon,
2006). IDO1 catalyzes the conversion of tryptophan to kynure-
nine and other downstream catabolites, which bind the aryl hy-
drocarbon receptor and that have been shown to inhibit Th17
differentiation (Desvignes and Ernst, 2009; Romani et al.,
2008). IDO1 activity, as measured by the ratio of kynurenine
to its parent compound tryptophan (Kyn:Trp) in blood plasma,
correlates strongly with the depletion of mucosal-barrier pro-
moting Th17 cells in the gut mucosa of HIV-infected subjects
(Favre et al., 2010; Vujkovic-Cvijin et al., 2013). It is postulated
that this disruption of mucosal immunity accounts for associa-
tions between IDO1 activity and microbial translocation (Chen
et al., 2014) as well as with peripheral immune activation (Jena-
bian et al., 2013, 2015) and mortality (Byakwaga et al., 2014)
in HIV-infected individuals. These observations support a role
for IDO1 activity in the pathophysiology of HIV/AIDS and high-
light the need for a greater understanding of the extrinsic andorts 13, 1589–1597, November 24, 2015 ª2015 The Authors 1589
host-mediated factors regulating the IDO1 pathway and the
depletion of Th17 cells in HIV/SIV infection.
Human-associated bacteria of the gastrointestinal tract
vastly outnumber host cells within each individual, and evi-
dence suggests that complex bidirectional relationships have
evolved between gut-resident microbes and the mammalian
mucosal immune system. Likely, selective pressures have
guided these relationships to facilitate a homeostasis wherein
the health of both host and microbe is maintained. Indeed,
Th17 cells and regulatory T cells (Treg) are poised at mucosal
surfaces where they interact with gut-resident microbes (Lath-
rop et al., 2011) and regulate their containment in the gut lumen
(Raffatellu et al., 2008); conversely, these cells themselves are
dynamically modulated by the presence of specific gut mi-
crobes (Ivanov et al., 2009; Atarashi et al., 2011). Uncovering
pathways by which gut-resident bacteria modulate mucosal
T cell differentiation is an active area of research. Putative mi-
crobial drivers of mucosal immune homeostasis in HIV/SIV dis-
ease, specifically those that may inhibit the immunomodulatory
IDO1 axis and/or otherwise preserve the Th17 cell pool, have
yet to be identified.
SIV-infected macaques provide a well-described non-human
primate model that recapitulates major features of HIV-associ-
ated chronic inflammation and mucosal immune disruption,
including innate and adaptive immune activation, CD4 T cell
depletion in the peripheral blood and gut-associated lymphoid
tissue, and a loss of mucosal barrier-promoting Th17 cells (Fa-
vre et al., 2009). The etiology of these immune disruptions in
the SIV-infected macaque model remain poorly understood,
though distinct assemblages of the macaque gut microbiome
have been shown to associate with abundance of Th17 cells
(Ardeshir et al., 2014). Furthermore, several recent macaque
studies have shown that members of the bacterial genus,
Lactobacillus, can modulate the Th17 axis, though mechanisms
for this process remain poorly understood. Administration of
VSL#3, a probiotic cocktail of seven bacterial species, four of
which are Lactobacillus spp., to chronically SIV-infected pigtail
macaques resulted in greater Th17 polyfunctionality as well as
a partial resolution of several inflammatory measures (e.g.,
lower fibrosis, reduced CD4 T cell activation, and increased
CD4 T cell recovery) (Klatt et al., 2013a; abstract by Ortiz
et al., 2014). In other studies, ligated ileal loops of acutely
SIV-infected rhesus macaques inoculated with Lactobacillus
plantarum displayed increased IL-17 expression and epithelial
tight junction formation (Hirao et al., 2014). Studies of the ma-
caque gut microbiome have shown few ecological differences
in gut bacterial communities between SIV-uninfected and
chronically SIV-infected macaques (Klatt et al., 2013a; Handley
et al., 2012; McKenna et al., 2008), which is in contrast to the
pronounced microbiota perturbations observed in human co-
horts (Lozupone et al., 2013; Dillon et al., 2014; Mutlu et al.,
2014; Dinh et al., 2015; Vujkovic-Cvijin et al., 2013). However,
host-microbiome dynamics during the acute phase of lentiviral
infection, when IDO1 is maximally induced by interferons,
remain unexplored. We found that a transient perturbation of
the fecal microbiota of SIV-infected macaques occurs during
acute SIV infection, which coincides with maximal IDO1 activ-
ity. This perturbation was characterized chiefly by depletion1590 Cell Reports 13, 1589–1597, November 24, 2015 ª2015 The Auof Lactobacillus members and we provide evidence here that
gut-resident Lactobacillus spp. modulate primate IDO1 by in-
hibiting production of immunomodulatory kynurenine com-
pounds that affect the Th17 cell arm of the mammalian mucosal
immune system.
RESULTS
A Transient Shift in Microbiota Composition Occurs
during Acute SIV Infection of Rhesus Macaques
Two temporally independent cohorts of six female rhesus ma-
caques were each experimentally infected with SIVmac251 and
followed longitudinally via stool and peripheral blood sampling
before infection and at five time points through the acute and
chronic infection phases. We profiled fecal bacterial microbiota
by sequencing of the V4 region of the 16S rRNA gene and
collapsing reads with 97% sequence homology into operational
taxonomic units (OTUs). A transient shift in the fecal microbiota
at 2 weeks post-SIV infection that subsided by 8 weeks post-
infection (Figure 1) was evident. These bacterial community dy-
namics were characterized by a decrease in alpha diversity
(Figure 1A) (a measure for community richness, i.e., the total
number of unique taxa and evenness, i.e., the relative disper-
sion of abundances of all taxa). This shift was characterized
also by an increase in beta diversity (defined as the composi-
tional difference between two ecological communities) within
each animal as compared to its own pre-infection time point,
using both the Canberra beta diversity metric (that weights
pair-wise distances by relative abundance of bacterial OTUs
present among both samples; Figure 1B) and the unweighted
UniFrac beta diversity metric (that incorporates a phylogenetic
relationship weighting of shared OTUs in distance calculations;
Figure S1). That a marked magnitude of microbiota com-
positional change occurred at 2 weeks post-infection was
supported by principal coordinates ordination (permANOVA
p = 0.039, Figure 1C). This analysis also demonstrated that
a significant change in composition was not evident when
comparing pre-infection communities to 8 weeks post-SIV
infection (p.i.) (permANOVA p = 0.194), further supporting the
observation that the greatest change in microbiota composition
occurred during the acute phase of SIV infection in this model.
Intriguingly, when comparing rhesus macaque fecal microbiota
at each time point to fecal microbiota of chronically HIV-in-
fected humans, there was no increase in similarity of the rhesus
macaque fecal microbiota to that of chronically HIV-infected
humans after SIV infection (Figure S1B), indicating that SIV
infection in this non-human primate model does not cause a
microbiota shift that resembles that of the HIV-associated gut
microbiota.
The Acute SIV-Associated Microbiota Shift Is
Characterized by Depletion of Lactobacillus spp. and Is
Paralleled in Early HIV Infection
To investigate taxonomic dynamics in microbiota composition
as a function of SIV infection (with a particular interest in the
2-week p.i. community), we compared OTU abundances pre-
infection to each time point after infection for each animal (Ta-
ble S1A). Notable differences were observed at 2 weeks p.i., atthors
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Figure 1. Ecological Dynamics of Microbiota Composition across SIV Infection in Rhesus Macaques
(A) Difference between baseline (pre-infection) and post-SIV infection (p.i.) fecal microbiota significantly increases at 2 weeks p.i. and returns by 8 weeks p.i.
(Wilcoxon matched-pairs signed rank test *p < 0.05, FDR Q value < 0.10). Each color represents a unique animal.
(B) Alpha diversity (richness and evenness) of the rhesusmacaque fecal microbiota drops at 2 weeks p.i. (Wilcoxonmatched-pairs signed rank test *p < 0.05, FDR
Q value < 0.05).
(C) Principal coordinates analysis (PCoA) plot of fecal microbiota shift from pre-infection to 2 weeks p.i. (p = 0.039 by permANOVA, stratified by individual,
Canberra beta diversity metric). No such shift is evident at 8 weeks p.i. (p = 0.194 by permANOVA, Canberra).
See also Figure S1.which time depletion of multiple Lactobacillus and Strepto-
coccus spp. occurred (Figure 2A; Table S1A). Lactobacillus
genus depletion was observed at 2 weeks p.i. in each of the
temporally independent cohorts of animals as well as when
considered together (Figure 2B; Table S1B), and this depletion
persisted into the chronic phase of infection 8 weeks p.i. (Fig-
ure 2B). Concomitant with these taxonomic depletions at
2 weeks p.i., IDO1 activity was heightened at this time point
and did not resolve to baseline (pre-infection) levels during
the chronic phase of infection (Figure 2C). This pattern of
IDO1 activity was similar in kinetics and relative scale to the
acute depletion of Lactobacillus, with a persistent but interme-
diate depletion extending into the chronic phase of SIV infec-
tion. In contrast to the rhesus macaque model used here, the
non-pathogenic SIV infection model of the African green mon-
key (a non-human primate which, when experimentally infected
with SIV, neither exhibits SIV-associated chronic inflammation
nor develops simian AIDS) (Jacquelin et al., 2009), restores
IDO1 activity to pre-infection levels during chronic infection.Cell RepThis coincides with an increased abundance of fecal Lactoba-
cillus at that time (Figure S2), suggesting a role for Lactobacilli
in the regulation of mammalian IDO1 activity during SIV infec-
tion. Furthermore, interrogation of fecal microbiomes using
the same methods described above for rhesus animals was
performed on a small cohort of subjects in the early stages of
HIV infection (time since infection for all infected subjects
<16 months, median time since last HIV RNA negative test =
175 days, detailed cohort characteristics in Table S1C). Anal-
ysis revealed all five OTUs within the Lactobacillaceae family
that were detected in our human dataset exhibited a decrease
in abundance as compared to HIV-uninfected, risk-matched
control human subjects (Table S1D). One such OTU was
significantly depleted (p = 0.019, false discovery rate [FDR]
Q value <0.10, Figure 2D), while the Lactobacillus genus
trended toward significance when comparing early HIV-in-
fected to uninfected subjects (p = 0.064, Figure 2E), suggesting
that depletion of Lactobacilli is a feature of acute lentiviral infec-
tion that is conserved among primates including humans.orts 13, 1589–1597, November 24, 2015 ª2015 The Authors 1591
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Figure 2. Gut Microbiota Taxonomic Shifts across Time in SIV-Infected Rhesus Macaques and in Early HIV Infection
(A) Shown areOTUs that differ significantly between pre-infection time point and each p.i. time point within each animal, withWilcoxonmatched-pairs signed rank
test p < 0.01 and mean read abundance fold change >2. Colors indicate the bacterial family to which each OTU belongs; the relative sizes of points are pro-
portional to the inverse log of Wilcoxon p values.
(B) Lactobacillus genus is depleted at 2 weeks p.i. and this depletion persists into the chronic phase of SIV infection at 8 weeks p.i. as compared to pre-infection.
Wilcoxon matched-pairs signed rank test was used for each comparison.
(C) Rhesus macaques exhibit elevated IDO1 activity that persists into the chronic phase of infection. Wilcoxon matched-pairs signed rank test, *p < 0.05,
**p < 0.005, ***p < 0.0005 for RM cohorts A and B considered together (black error bars).
(D) Lactobacillus sp. OTU 292057 is significantly depleted in the stool of early HIV-infected human subjects as compared to uninfected risk-matched controls
(p = 0.019). Dataset used for this analysis was rarified to 97,000 reads per sample.
(E) Fecal Lactobacillus genus abundance trends toward significant depletion in early HIV-infected human subjects as compared to uninfected controls
(p = 0.0641).
See also Figure S2 and Table S1.LactobacillusDepletion Associates with Increased IDO1
Activity and Loss of Th17 Cell Abundance
To further narrow the candidate bacterial taxa thatmaymodulate
IDO1 activity, we used a linear mixed effects models approach
(that accounts for inter-individual variation in longitudinal time-
series data) to compare abundances of all bacterial genera de-
tected in all rhesus animals at all time points to respective
plasma Kyn:Trp ratios. We found that fecal abundance of the
Lactobacillus genus correlated significantly and inversely with1592 Cell Reports 13, 1589–1597, November 24, 2015 ª2015 The AuIDO1 activity (p = 0.00151, Figure 3A) and was the top inverse
correlate of all genera detected in our dataset (total = 86, Table
S2A). Furthermore, IDO1 activity was found to be tightly corre-
lated with peripheral blood Th17 cell loss across acute and
chronic SIV infection (p = 0.0000052, Figure 3B). Accordingly,
the abundance of the Lactobacillus genus exhibited a significant
positive correlation with Th17 cell abundances (p = 0.00187, Fig-
ure 3C) and was among the strongest taxonomic correlates of
Th17 cell abundances in our dataset (Table S2B). To addressthors
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Figure 3. IDO1 Activity and Th17 Cell Dynamics Associate with Loss of Gut-Resident Lactobacillus
(A) The abundance of Lactobacillus genus correlates strongly with IDO1 activity as measured by Kyn:Trp ratios in peripheral blood. Linear mixed effects (LME)
modeling was used to allow for inclusion of longitudinal data from each animal and to test for correlations between all detected bacterial families and IDO1 activity
(peripheral blood Kyn:Trp ratios). Linear regression lines are shown in black.
(B) IDO1 activity (Kyn:Trp) correlates strongly and significantly with Th17 cell abundances in peripheral blood of RM, using LME modeling.
(C) Lactobacillus abundance correlates with Th17 cell abundance in peripheral blood. As with (B), LME modeling was used to test for correlations between all
bacterial families detected and peripheral blood Th17 cell abundance, as assessed by flow cytometry gating the percentage of IL-17+ of total CD4+ cells.
See also Figure S3 and Table S2.the hypothesis that other fecal taxa that correlated positively with
IDO1 activity may themselves produce kynurenine compounds,
we utilized the UniProt genome database to identify bacterial
families that encode enzymes that participate in the kynurenine
pathway of tryptophan catabolism. We found that families that
encode such enzymes do not preferentially correlate with
Kyn:Trp ratios (Figure S3A), suggesting that direct bacterial tryp-
tophan catabolism may not represent the primary driver of
Kyn:Trp ratios in the SIV-infected rhesus macaque.
To understand whether the inverse correlation between IDO1
activity and Lactobacillus abundance found in our rhesus ma-
caque cohorts was due to antagonistic effects of kynurenine
on Lactobacillus growth, we isolated Lactobacillus spp. from
the stool samples obtained from experimental animals. The re-
sulting primary isolates were dominated by L. animalis and
L. reuteri (Figure S3B). Physiologic and supraphysiologic con-
centrations of kynurenine were added to growth cultures of
L. animalis and L. reuteri isolates, and growth was measured
by light absorption. No effect of kynurenine on the growth of
these primary isolates was observed (Figure S3C).
Supplementation of SIV-Infected Macaques with a
Lactobacillus-Containing Probiotic Reduces Peripheral
Blood IDO1 Activity
To further investigate cause and effect relationships responsible
for the correlation between Lactobacillus genus abundance and
activity of the immunomodulatory IDO1 pathway, we asked
whether supplementation of SIV-infected macaques with Lacto-
bacillus spp. may modulate IDO1 activity in vivo. Plasma was
analyzed from two cohorts of SIV-infected pigtail macaques
that had initiated treatment with VSL#3, a probiotic mixture
composed of seven bacterial strains of which four are Lactoba-
cillus spp., 12 weeks post SIV infection (Klatt et al., 2013a; ab-
stract by Ortiz et al., 2014). While only a subset of animals
were administered VSL#3, all animals received antiretroviral
therapy as detailed in the Experimental Procedures. As deter-Cell Repmined using linear mixed effects models to control for be-
tween-cohort differences, VSL#3-treated animals at days 325–
373 p.i. exhibited significantly decreased plasma concentrations
of kynurenine, an effector molecule produced through IDO1
catabolism of tryptophan, as compared to untreated control an-
imals (Figure 4A). These animals also exhibited trends toward
lower ratios of Kyn:Trp (Figure 4B), a marker of flux through the
IDO1 catabolic pathway, and differences in both kynurenine
concentration and Kyn:Trp ratios at the 325–372 days p.i. time
point as compared to the same measurements in pre-infection
plasma. While one of the two cohorts treated with VSL#3
received an additional agent (the Th17-promoting IL-21 cyto-
kine, which has no reported relationships to IDO1 activity),
there were no differences in Kyn:Trp ratios or kynurenine con-
centrations between the VSL#3-treated arms of these cohorts
(Figure S4).
DISCUSSION
Weobserved a specific depletion of gut-resident Lactobacillus in
rhesus macaques, seen most dramatically during acute SIV
infection and persisting into the chronic phase. This depletion
correlated with increased IDO1 activity and Th17 cell loss across
time during SIV infection. The kynurenine product of the IDO1
pathway was found to have no effect on Lactobacillus growth
in vitro, while pigtail macaques supplemented with a Lactoba-
cillus-containing probiotic exhibited decreased IDO1 activity
during chronic SIV infection. We propose that gut-resident
Lactobacillus species inhibit primate IDO1 and thus may help
to preserve the Th17 cell compartment during pathogenic SIV
infection. If so, Lactobacillus species may be beneficial modula-
tors of mucosal immune homeostasis during the course of such
infection.
Furthermore, we profiled the fecal microbiota of several Afri-
can green monkeys at different stages of SIV infection. In
contrast to SIV-infected macaques, African green monkeysorts 13, 1589–1597, November 24, 2015 ª2015 The Authors 1593
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Figure 4. Effects of Supplementation of SIV-Infected Pigtail Macaques with a Lactobacillus-Containing Probiotic onMarkers of IDO1Activity
(A) Two cohorts of pigtail macaques (PTMs) given daily VSL#3 exhibit a decrease in peripheral blood kynurenine concentrations compared to untreated control
PTMs at days 325–372 p.i., p = 0.046, by LME.
(B) Trends toward significance in Kyn:Trp ratios are seen in PTMs treated with VSL#3 at days 325–372 p.i. (p = 0.091).
See also Figure S4.exhibit a non-pathogenic course of SIV infection characterized
by a resolution of IDO1 activity during the chronic phase and a
preservation of the Th17 cell pool (Favre et al., 2009). We found
that these animals instead exhibited an increase in fecal Lacto-
bacillus abundance during chronic infection, consistent with a
role for Lactobacillus in inhibiting the IDO1 pathway. However,
these observations were obtained from a small, cross-sectional
sample size of mixed gender (n = 4–6 for pre-infection, acute,
and chronic SIV-infected animals), whereas our rhesus cohorts
were female and should be interpreted cautiously at this time.
Additionally, the power to detect differences between VSL#3-
treated and untreated SIV-infected animal groupswas enhanced
by the combination of two temporally separated VSL#3 supple-
mentation experiments. One of these trials included administra-
tion of the cytokine IL-21 in addition to VSL#3. To our knowledge,
no precedence exists for IL-21 directly affecting IDO1 activity,1594 Cell Reports 13, 1589–1597, November 24, 2015 ª2015 The Aualthough this possibility cannot be ruled out. Despite this, plasma
kynurenine concentrations and Kyn:Trp ratios did not differ
significantly between the cohort that received IL-21 and that
which did not, suggesting that the interpretation of the effect be-
ing largely due to the VSL#3 probiotic may be appropriate.
Furthermore, while Lactobacillus has been previously associated
with lower peripheral blood kynurenine in rats (Valladares et al.,
2013), mono-administration of a Bifidobacterium sp. contained
in VSL#3 did not affect peripheral blood kynurenine levels (Bercik
et al., 2010), while products of the other genus composing
VSL#3, Streptococcus, have been shown to induce rather than
inhibit IDO1 activity (Murr et al., 2001).
While shifts in the gut bacterial microbiota of chronically HIV-
infected humans have been well-described and with relative
consistency in findings, several studies (including that pre-
sented herein) suggest that significant ecological shifts in thethors
gut bacterial microbiota do not occur in macaques in the
chronic phase of experimental SIVmac251 (Handley et al.,
2012; McKenna et al., 2008) or SIVmac239 (Klatt et al., 2013a)
infection as compared to uninfected macaques. We observed
that a pronounced depletion of Lactobacillus occurs during
acute SIV infection and appears to occur also during early
HIV infection, though our cohort of HIV-infected humans was
small (n = 5). This suggests that similarities do exist between
the experimental SIV infection model of rhesus macaques
and HIV-infected humans in the early phases of infection. How-
ever, numerous studies of HIV-associated microbiota shifts
have reported no changes in the abundance of gut Lactoba-
cillus during chronic HIV infection in humans (Lozupone et al.,
2013; Dillon et al., 2014; Mutlu et al., 2014; Dinh et al., 2015;
Vujkovic-Cvijin et al., 2013), while we observed that Lactoba-
cillus depletion persists into chronic SIV infection. As chronic
HIV-associated microbiota shifts may be relevant to HIV dis-
ease pathogenesis, knowledge of this distinction as a potential
caveat to the macaque model of experimental SIV infection
may inform interpretation of results from this important model.
Regardless, however, of its incapacity to recapitulate chronic
HIV-associated microbiota shifts at the taxonomic level, the
macaque model offers various notable advantages toward
probing host-microbiome immunologic relationships, including
genomic proximity to humans and a higher capacity for tissue
sampling across time.
Lactobacillus-supplemented yogurt has been investigated as
a possible therapeutic agent in African cohorts of treated and un-
treated HIV-infected adults, with results showing improvements
in CD4 count through mechanisms that remain poorly under-
stood (Anukam et al., 2008; Irvine et al., 2010). Extrapolating
from the findings of this study, we propose that Lactobacilli
may inhibit IDO1 activity of humans as well as of non-human pri-
mates, an effect that may have the capacity to mitigate the loss
of gut barrier-promoting human Th17 cells. This could allow for
maintenance of mucosal integrity, reduction in microbial translo-
cation, and an overall diminution of HIV-associated inflamma-
tion. This proposal could be directly tested in clinical trials using
existing, over-the-counter probiotics (e.g., VSL#3) containing
Lactobacillus spp. and should be carried out with a focus on
IDO1 activity as an outcome.EXPERIMENTAL PROCEDURES
Study Cohorts and Sample Collection
Six female rhesus macaques (Macaca mulatta) were infected with
SIVmac251-2010 on April 23, 2013 (cohort A) and eight more females were in-
fected on July 16, 2013 (cohort B) with 100 TCID50 administered intravenously
(i.v.). Peripheral blood plasma and stool were collected and stored at80C at
the following days relative to the dates of infection for all rhesus macaque an-
imals: 7, 3, 7, 10, 14, and 56 days, while peripheral blood mononuclear cells
(PBMCs) were obtained and cryopreserved at 80C at days 7, 14, and 56
post-infection. A total of 14 African green monkeys (AGMs) (Chlorocebus
sabaeus) were used in this study as part of cohort C shown in Figure S2. Twelve
AGMs were adult males and two were female. All AGMS were 6–11 years of
age. Six AGMs were uninfected, while eight AGMs were intra-rectally (i.r.)-in-
fected with plasma containing 107 copies of SIVagm.sab92018. Peripheral
blood and stool were collected at the following days relative to the dates of
infection for all AGMs: 30, 9–13, and 46–56 days. Human subject fecal sam-
ples were self-collected and deposited at 80C without preservative withinCell Rep6 hr of stool deposition. Peripheral blood plasma was collected at time of
deposition and stored at 80C.
Fecal Sample Processing, 16S rRNA Amplification, and 16S rRNA
Sequencing
Fecal sample DNA was extracted and DNA was amplified targeting the V4 re-
gion of the 16S rRNA gene. Microbiome profiling was performed on eleven an-
imals at all fecal time points collected, while the remaining three animals were
profiled at 7, 14, and 56 days p.i. Amplification, pooling, purification, and
quantification was performed as described in the Supplemental Experimental
Procedures. 16S rRNA sequencing data have been deposited at theQiita data-
base: Study ID 10257 (http://qiita.microbio.me).
16S rRNA Sequence Analysis and Statistical Methods
An open-reference OTU picking scheme was utilized as implemented in the
QIIME software package and reads were rarefied to 34,000 per sample.
Beta diversity and alpha diversity calculations were performed in QIIME, while
the R package ‘‘adonis’’ was used to calculate permANOVA statistics. Custom
R scripts were designed to identify discriminating OTUs after SIV infection and
to compare abundances of all bacterial families to peripheral blood IDO1 ac-
tivity and Th17 cell abundances. Comparisons of RM fecal microbiomes to
HIV-infected humans were made using fecal 16S sequencing data published
previously (Lozupone et al., 2013) and beta diversity metrics were calculated
using QIIME.
Flow Cytometry and Analysis
PBMCs were isolated from rhesus macaque peripheral blood, cryopreserved,
stimulatedwith phorbol 12-myristate 13-acetate + ionomycin, and analyzed by
flow cytometry as described in the Supplemental Experimental Procedures.
IDO Activity Measurements
IDO activity wasmeasured as the ratio of the plasma concentration of its enzy-
matic product, kynurenine, to concentration of its parent compound, trypto-
phan. Concentrations of kynurenine and tryptophan were quantitated in the
plasma of all animals within the present study by liquid chromatography-tan-
dem mass spectrometry, as previously described (Favre et al., 2010).
VSL#3 Trial Characteristics and Analysis
Two separate studies using pigtail macaques (Macaca nemestrina) infected
with 3,000 TCID of SIVmac239 i.v. were combined for analysis of the effects of
VSL#3 treatment on IDO1 activity. One cohort, initiated on 6/25/2010 (Klatt
et al., 2013a), consisted of four control animals and seven VSL#3-treated
animals, with VSL#3-treated animals beginning daily administration of
probiotic beginning at 100 days post-infection and both groups beginning
antiretroviral therapy at day 160 post-infection as described previously
(Klatt et al., 2013a). The second cohort, initiated on October 9, 2012, con-
sisted of five control animals and six VSL#3/IL-21-treated animals, with an-
tiretroviral therapy commencing on day 98 p.i. for both groups and the
VSL#3/IL-21 group receiving daily VSL#3 beginning on day 98 p.i. as well
as two courses of rMamu IL-21-IgFc (50 mg/kg at 1 mg/ml in H2O subcuta-
neously [s.c.], five once-weekly doses) initiated at days 98 and 333 p.i. as
described (abstract by Ortiz et al., 2014). One animal in the control group
for the second cohort was sacrificed before the study end due to severe
diarrhea. Linear mixed effects modeling fitted by maximum likelihood (R
package ‘‘lme4’’) was used to test the significance of differences between
VSL#3-treated and untreated animals, incorporating stratification by study
cohort.
Lactobacillus Isolation and In Vitro Experimentation
Lactobacillus primary isolates were isolated by plating frozen stool from ani-
mals in cohort B onto MRS selection agar (Becton Dickinson). Full-length
16S rRNA sequencing to verify taxonomic identity of resultant isolates was
performed using the 27f/1492r 16S rRNA primer pair. Taxonomy was assigned
to sequence reads using NCBI BLAST (http://blast.ncbi.nlm.nih.gov/Blast.
cgi). Growth assessment with addition of exogenous kynurenine was per-
formed in MRS liquid media at 37C using an automated spectrophotometer
with OD600 readings taken at regular intervals.orts 13, 1589–1597, November 24, 2015 ª2015 The Authors 1595
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